Neurocrine Biosciences Reports Second Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Neurocrine Biosciences (NBIX) Tops Q2 EPS by 43c, Revenues Beat
July 29, 2019 4:54 PM EDTNeurocrine Biosciences (NASDAQ: NBIX) reported Q2 EPS of $0.54, $0.43 better than the analyst estimate of $0.11. Revenue for the quarter came in at $183.6 million versus the consensus estimate of $163.14 million.
"Over the past two years, our team has done an excellent job building awareness of tardive dyskinesia within the healthcare community and providing patients... More
